Diabetes

Missed sessions are the obvious place where digital programs can find a place in the launch of Medicare's first fully reimbursed preventive service.

After taking recommendations from providers, Mississippi lawmakers pass a bill that would end caps on prescription drugs and office visits in Medicaid.

This week, the top managed care stories included another insurer announcing it would pass on drug rebates to consumers; FDA approved a new continuous glucose monitor and created a new medical device class; new guidelines address how to treat people with both HIV and cancer.

With Medicaid consuming a larger share of the Mississippi's budget, innovative solutions were needed to deliver improved health outcomes at a lower cost. A public-private partnership was created to pursued a population health strategy aimed at reducing preterm births and preventing the progression of prediabetes to type 2 diabetes.

Brenda Schmidt, CEO of Solera Health, discusses how Solera has been getting ready for the launch of the Medicare Diabetes Prevention Program on April 1, 2018.

In a 2-pronged move, the FDA approved the sale of the Dexcom G6 integrated continuous glucose monitoring system for determining blood glucose levels and also classified the unit as a class II medical device, enabling a speedier review for similar future systems.

The lead researcher said the study could lead to women being given a statin as soon as they are diagnosed with endometrial cancer.

A case filed more than a year ago has taken many turns, landing in a federal court in Trenton, where it has been shaped by a difference of opinion over how to address the role of pharmacy benefit managers (PBMs).

Adherence may play a role in the real-world findings of the study, which was sponsored by Janssen.

The study compared patients taking semaglutide with those taking placebo and liraglutide, which is approved for treatment of obesity.

New health statistics from the US government paint a picture of a population that is more obese and more prone to diabetes than it was 20 years ago. On the bright side, however, more people have health insurance.

CVD-REAL, the giant study of real-world evidence comparing sodium glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs to treat type 2 diabetes, found a 49% lower risk of all-cause death and a host of other benefits across 6 new, more diverse countries, the study’s lead author told a packed room Sunday at the 67th Scientific Session of the American College of Cardiology in Orlando, Florida.

The study will be presented during the 67th American College of Cardiology Scientific Session in Orlando, Florida.

HHS Secretary Alex Azar said the administration will announce actions to lower healthcare costs, as well as a move to give patients control of their data; doctors and patients with chronic pain oppose proposed prescribing limits sought by CMS for opioids; doctor groups are disagreeing about blood sugar targets for patients with diabetes.

On Friday, Novo Nordisk announced the results from PIONEER 1, a phase 3a trial featuring oral semaglutide for treatment of adults with type 2 diabetes (T2D). Oral semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue taken once daily as a tablet, making this investigational therapy the first oral treatment in this class.

In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.

There is a lot of energy around educating consumers about their risk for type 2 diabetes, explained Brenda Schmidt, CEO of Solera Health.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included a report from CMS that found healthcare spending will rise 5.5% over the next 8 years; the budget deal passed by Congress included a number of provisions with long-term health impact; a study found eating a low-carb could help reverse type 2 diabetes.

Patients with diabetes receiving insulin treatment with lower cost sharing for blood glucose testing strips were more likely to achieve glycemic control than those with higher cost sharing.

Flatiron Health expects to maintain its current business model in the transaction.

The study used a claims database to examine records from patients who switched between long-acting insulins.

Language in the new government budget ensures effective changes to CMS' Competitive Bidding Program for diabetes testing supplies that will benefit patients with diabetes.